Search the Israeli drug index

Drug class Cross-linked polyacrylic acid sodium salt, hydroxy propyl
methyl cellulose (HPMC), titanium dioxide, cellulose acetate
phthalate, hydroxypropyl cellulose, chitosan, diethyl
phthalate, polyvinyl alcohol polyethylene copolymer
(Kollicoat), triethyl citrate, cellulose acetate, acetyl tributyl
citrate.
Caps. X 56
1 cap. before meal X 2/d
Reducing BW in pts with 25 < BMI < 40 in conjunction with diet and exercise.
C/I: Hypersens. Pregn

Corticosteroid. Budesonide 2 mg.
Canister  with 14 X of 1.2  g
One actuation of 2 mg /d
Tmt of act. ulcerative colitis limited to the rectum and the sigmoid colon
C/I:  Hypersens. /hepatic cyrrhosis

Anti-CD20, Human Monoclonal Antibody. Ocrelizumab 40 mg/ml.
Vial. 1 X 920 mg for SC inject.
single 23 mL in the abdomen over approx. 10 minutes every 6 months.
For adults with relapsing or primary progress. forms of multiple sclerosis.
C/I:Hypersens. Active HBV infection/ A hist. of life-threatening admin. reaction to ocrelizumab

Sodium Chloride 5%.
Eye drops. solut., 10 ml
To use as needed
* Visual discomfort, burning and eye irritat. caused by corneal oedema

* In the case of abnormal fluid accumulat. caused by corneal oedema, with or without inflamm. or blunt trauma after refractive or ophthalmic surgery, cataracts, transplants, retinal detachments, corneal transplants, corneal endothelial decompensation and in all dystrophic, mechanical, toxic and inflammatory corneal decompensations.

Antivirals, Protease Inhibitors. nirmatrelvir 150 mg, Ritonavir 100 mg.
20 X FC pink tabs contain.150 mg of nirmatrelvir.
10 XFC white to off white tabs contain.100 mg of ritonavir.
Recomm. dosage is 300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet) all taken together orally every 12 hours for 5 days. This drug should be admin. as soon as possible after a diagnosis of COVID-19 has been made and within 5 days of symptom onset.
Tmt. of confirmed coronavirus dis. 2019 (COVID-19) in adults
who do not require suppl. oxygen and who are at incr. risk for progressing to sev. COVID-19
C/I:  Hypersens.
Medic. prod. listed below are a guide and not considered a comprehensive list of all possible medic. prod. that are contraind. with this drug.
Medic. prod. that are highly dependent on CYP3A for clearance and for which elevated plasma concentr. are associated with serious and/or life-threatening reactions.
 Alpha1-adrenoreceptor antagonist: alfuzosin
 Antianginal: ranolazine
 Antiarrhythmic: dronedarone, propafenone, quinidine
 Anticancer drugs: neratinib, venetoclax
 Anti-gout: colchicine
 Antihistamines: terfenadine
 Antipsychotics/neuroleptics: lurasidone, pimozide, quetiapine
 Benign prostatic hyperplasia medicinal products: silodosin
 Cardiovascular medicinal products: eplerenone, ivabradine
 Ergot derivatives: dihydroergotamine, ergonovine, ergotamine, methylergonovine
 GI motility agents: cisapride
 Immunosuppressants: voclosporin
 Lipid-modifying agents:
o HMG Co-A reductase inhibitors: lovastatin, simvastatin
o Microsomal triglyceride transfer protein (MTTP) inhibitor: lomitapide
 Migraine medicinal products: eletriptan
 Mineralocorticoid receptor antagonists: finerenone
 Neuropsychiatric agents: cariprazine
 Opioid antagonists: naloxegol
 PDE5 inhibitor: avanafil, sildenafil, tadalafil, vardenafil
 Sedative/hypnotics: clorazepate, diazepam, estazolam, flurazepam, oral midazolam and triazolam
 Vasopressin receptor antagonists: tolvaptan
Medic. prod. that are potent CYP3A inducers where significant. reduced nirmatrelvir/ritonavir plasma concentr. may be associated with the potential for loss of virologic response and possible resistance.
 Antibiotics: rifampicin, rifapentine
 Anticancer drugs: apalutamide, enzalutamide
 Anticonvulsants: carbamazepine, phenobarbital, phenytoin, primidone
 Cystic fibrosis transmembrane conductance regulator potentiators: lumacaftor/ivacaftor
 Herbal products: St. John's wort (Hypericum perforatum)
This drug cannot be started immediately after discontinuation of CYP3A4 inducers due to the delayed offset of the recently discontinued CYP3A4 inducer.

Centrally Acting Sympathomimetics. Lisdexamfetamine 10 mg/ml.
Bottle, oral sol. 100 ml
ADHD: starting dosage in adults and ped. pts 6 years and older is 30 mg (equivalent to 3 ml) once/d in the morning. Dosage may be adj. in incr. of 10 mg (equivalent to 1 ml) or 20 mg (equivalent to 2 ml) at approx. weekly intervals up to max. dosage of 70 mg (equivalent to 7 ml) once/d.
Moderate to Severe BED in Adults: starting dosage in adults is 30 mg (equivalent to 3 ml) once /d to be titrated in incr. of 20 mg (equivalent to 2 ml) at approx. weekly intervals to achieve target dose of 50 to 70 mg (equivalent to 5 ml to 7 ml) once daily. The max. dosage is 70 mg/once daily (equivalent to 7 ml/once daily).
See prescribing info. for full details.
• Attention Deficit Hyperactivity Disorder (ADHD) in pts. ages 6 years and above.
• Mod. to Sev. Binge Eating Dis.(BED) for pts over 18 years.
C/I:Hypersens. Known hypersens. to amphetamine prod. Anaphylactic reactions, Stevens Johnson Syndrome, angioedema, and urticaria have been observed in post-marketing reports./Pts taking monoamine oxidase inhibit. (MAOIs), or within 14 days of stopping MAOIs (incl. MAOIs such as linezolid or intravenous methylene blue), because of an incr. risk of hypertensive crisis